9
Participants
Start Date
December 15, 2024
Primary Completion Date
August 15, 2025
Study Completion Date
August 15, 2026
IM96 CAR-T Cells
IM96 CAR-T Cells, 12×10\^8 CAR-T cells, 20×10\^8 CAR-T cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D- 3), determined by tumor burden at baseline. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 300 mg/ m\^2 (D-5\~D-3), determined by tumor burden at baseline.
RECRUITING
Beijing Cancer Hospital, Beijing
Peking University Cancer Hospital & Institute
OTHER
Beijing Immunochina Medical Science & Technology Co., Ltd.
INDUSTRY